BCR and diffuse large B-cell lymphoma: Preclinical studies demonstrated that co-administration of the BCR inhibitor ibrutinib with the proteasome inhibitor bortezomib synergistically increased mitochondrial injury and apoptosis in highly bortezomib-resistant GCB and ABC-DLBCL in vitro [561].